フックス角膜内皮ジストロフィ（FECD）- 世界市場の考察、疫学、市場予測（2034年）

主なハイライト

• フックス角膜内皮ジストロフィ（FECD）市場は、予測期間（2023年～2034年）を通して安定した成長が見込まれます。主要7市場におけるFECDの市場規模は、新治療法の上市による拡大が見込まれます。
• DelveInsightのアナリストは、主要7市場のFuchs Endothelial Corneal Dystrophy（FECD）と診断された総患者数のうち、約35％が米国の患者であると予測しています。当社の推計によると、2022年、欧州4ヶ国・英国のFECDと診断された有病者数は約920万人です。
• 主要7市場では、市場は主に標準治療（高浸透圧性塩化ナトリウム、ステロイドなど）で構成され、2022年に約8億5,000万米ドルを創出しました。
• フックス角膜内皮ジストロフィ（FECD）治療市場の総市場規模は、リパスジル/K-321、TTHX1114/NM141などの新しい効果的な治療法の登場により、予測期間に成長する見込みです。

フックス角膜内皮ジストロフィ（FECD）市場の見通し

FECDには、疾患情勢に関連した多様な治療分類があります。FECDの管理は主に、高浸透圧性塩化ナトリウム、ステロイド、必要に応じたその他の薬剤の使用を中心に行われます。

標準治療（高浸透圧性塩化ナトリウム、ステロイドなど）は、現在の治療情勢における主な収益源です。

FECD市場は、Ripasudil/K-321、TTHX1114/NM141などのような潜在的な薬剤の承認により、プラス成長が予測されます。

• 主要7市場のFECDの総市場規模は、2022年に約8億5,000万米ドルに達しました。予測期間に大幅な成長が見込まれます。
• 主要7市場のうち、米国が2022年に市場を独占し、約46％の最大シェアを占めました。
• 2022年、欧州4ヶ国・英国が推定3億3,000万米ドルを獲得し、これは大幅なCAGRで増加すると予測されています。欧州諸国の中では、ドイツが2022年に最大の市場シェアを占め、イタリア、フランス、英国がこれに続きます。スペインは同年の市場シェアが最小でした。
• 日本は単独で2022年にFECD市場全体の約16％を占め、調査期間に大幅なCAGRで増加すると予測されました。
• FECD治療市場の総市場規模は、新しい効果的な治療法の登場により、予測期間に成長が見込まれます。

当レポートでは、フックス角膜内皮ジストロフィ（FECD）の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 FECD市場の概要

• FECDの市場シェア分布（2020年）
• FECDの市場シェア分布（2034年）

第4章 FECDの疫学と市場の調査手法

第5章 FECDのエグゼクティブサマリー

第6章 重要な出来事

第7章 疾患の背景と概要

• イントロダクション
• 角膜ジストロフィの種類
• 臨床症状
• 兆候と症状
• 危険因子
• 遺伝と継承
• 病因
• 予後
• 病期
• 診断
• 治療と管理

第8章 疫学と患者人口

• 主な調査結果
• 前提条件と根拠：主要7市場
• 主要7市場のFECDと診断された総患者数
• 米国
• 欧州4ヶ国・英国
• 日本

第9章 ペイシェントジャーニー

第10章 新薬

• 主な競合
• Ripasudil (K-321): Kowa Pharmaceuticals
• TTHX 1114: Trefoil Therapeutics

第11章 FECD：市場の分析

• 主な調査結果
• 主な市場予測の前提条件
• 市場見通し
• コンジョイント分析
• 主要7市場のFECDの市場規模
• 主要7市場のFECDの市場規模：治療法別
• 米国のFECDの市場規模
• 欧州4ヶ国・英国のFECDの市場規模
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本のFECDの市場規模

第12章 KOLの見解

第13章 SWOT分析

第14章 アンメットニーズ

第15章 市場参入

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

List of Tables

• Table 1: Summary of FECD Market and Epidemiology (2020-2034)
• Table 2: Key Events
• Table 3: Management of FECD
• Table 4: Total Diagnosed Prevalent Cases of FECD in the 7MM, in Thousands (2020-2034)
• Table 5: Total Diagnosed Prevalent Cases of FECD in the US, in Thousands (2020-2034)
• Table 6: Gender-specific Cases of FECD in the US, in Thousands (2020-2034)
• Table 7: Age-specific Cases of FECD in the US, in Thousands (2020-2034)
• Table 8: Grade-specific Cases of FECD in the US, in Thousands (2020-2034)
• Table 9: Total Diagnosed Prevalent Cases of FECD in the EU4 and the UK, in Thousands (2020-2034)
• Table 10: Gender-specific Cases of FECD in the EU4 and the UK, in Thousands (2020-2034)
• Table 11: Age-specific Cases of FECD in the EU4 and the UK, in Thousands (2020-2034)
• Table 12: Grade-specific Cases of FECD in the EU4 and the UK, in Thousands (2020-2034)
• Table 13: Total Diagnosed Prevalent Cases of FECD in Japan, in Thousands (2020-2034)
• Table 14: Gender-specific Cases of FECD in Japan, in Thousands (2020-2034)
• Table 15: Age-specific Cases of FECD in Japan, in Thousands (2020-2034)
• Table 16: Grade-specific Cases of FECD in Japan, in Thousands (2020-2034)
• Table 17: Comparison of Emerging Drugs Under Development
• Table 18: Ripasudil (K-281), Clinical Trial Description, 2024
• Table 19: TTHX1114, Clinical Trial Description, 2024
• Table 20: Key Market Forecast Assumptions for Ripasudil (K-281)
• Table 21: Key Market Forecast Assumptions for TTHX 1114
• Table 22: Market Size of FECD in the 7MM, in USD million (2020-2034)
• Table 23: Market Size of FECD by Therapies in the 7MM, in USD million (2020-2034)
• Table 24: Market Size of FECD in the US, in USD million (2020-2034)
• Table 25: Market Size of FECD by Therapies in the US, in USD million (2020-2034)
• Table 26: Market Size of FECD in the EU4 and the UK, in USD million (2020-2034)
• Table 27: Market Size of FECD by Therapies in Germany, in USD million (2020-2034)
• Table 28: Market Size of FECD by Therapies in France, in USD million (2020-2034)
• Table 29: Market Size of FECD by Therapies in Italy, in USD million (2020-2034)
• Table 30: Market Size of FECD by Therapies in Spain, in USD million (2020-2034)
• Table 31: Market Size of FECD by Therapies in the UK, in USD million (2020-2034)
• Table 32: Market Size of FECD by Therapies in the EU4 and the UK, in USD million (2020-2034)
• Table 33: Market Size of FECD in Japan, in USD million (2020-2034)
• Table 34: Market Size of FECD by Therapies in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Signs and Symptoms Involved in FECD
• Figure 2: Risk Factors Involved in FECD
• Figure 3: Mechanisms Involved in the Pathogenesis of FECD
• Figure 4: Differential Diagnosis of FECD
• Figure 5: Total Diagnosed Prevalent Cases of FECD in the 7MM (2020-2034)
• Figure 6: Total Diagnosed Prevalent Cases of FECD in the US (2020-2034)
• Figure 7: Gender-specific Cases of FECD in the US (2020-2034)
• Figure 8: Age-specific Cases of FECD in the US (2020-2034)
• Figure 9: Grade-specific Cases of FECD in the US (2020-2034)
• Figure 10: Total Diagnosed Prevalent Cases of FECD in the EU4 and the UK (2020-2034)
• Figure 11: Gender-specific Cases of FECD in the EU4 and the UK (2020-2034)
• Figure 12: Age-specific Cases of FECD in the EU4 and the UK (2020-2034)
• Figure 13: Grade-specific Cases of FECD in the EU4 and the UK (2020-2034)
• Figure 14: Total Diagnosed Prevalent Cases of FECD in Japan (2020-2034)
• Figure 15: Gender-specific Cases of FECD in Japan (2020-2034)
• Figure 16: Age-specific Cases of FECD in Japan (2020-2034)
• Figure 17: Grade-specific Cases of FECD in Japan (2020-2034)
• Figure 18: Patient Journey
• Figure 19: Market Size of FECD in the 7MM, in USD million (2020-2034)
• Figure 20: Market Size of FECD by Therapies in the 7MM, in USD million (2020-2034)
• Figure 21: Market Size of FECD in the US, in USD million (2020-2034)
• Figure 22: Market Size of FECD by Therapies in the US, in USD million (2020-2034)
• Figure 23: Market Size of FECD in the EU4 and the UK, in USD million (2020-2034)
• Figure 24: Market Size of FECD by Therapies in the EU4 and the UK, in USD million (2020-2034)
• Figure 25: Japan Market Size of FECD, in USD million (2020-2034)
• Figure 26: The Japan Market Size of FECD by Therapies, in USD million (2020-2034)
• Figure 27: Health Technology Assessment
• Figure 28: Reimbursement Process in Germany
• Figure 29: Reimbursement Process in France
• Figure 30: Reimbursement process in Italy
• Figure 31: Reimbursement Process in Spain
• Figure 32: Reimbursement Process in Japan

Key Highlights:

• The Fuchs Endothelial Corneal Dystrophy (FECD) market is projected to witness consistent growth throughout the forecast period (2023-2034). The market size of FECD in the 7MM is expected to increase, driven by the launch of emerging therapies.
• DelveInsight's analyst projects that among the Total Diagnosed Prevalent Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM approximately 35% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 9.2 million diagnosed prevalent cases of FECD.
• In the 7MM, the market mainly consisted of Standard of care (Hyperosmotic sodium chloride, Steroids, etc.), which generated nearly USD 850 million in 2022.
• The total market size of the Fuchs Endothelial Corneal Dystrophy (FECD) treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Ripasudil/K-321, TTHX1114/NM141, and others.

DelveInsight's "Fuchs Endothelial Corneal Dystrophy (FECD) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the FECD, historical and forecasted epidemiology and the FECD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Fuchs Endothelial Corneal Dystrophy (FECD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM FECD market size from 2020 to 2034. The report also covers current FECD treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Treatment Algorithm

Fuchs Endothelial Corneal Dystrophy (FECD) Overview

Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive hereditary disease affecting the cornea's endothelial layer. It is characterized by corneal edema, guttae formation, reduced visual acuity, and can lead to corneal blindness. FECD is more common in women, and its prevalence varies geographically in the 7MM. FECD is associated with genetic factors, with mutations in genes like COL8A2, SLC4A11, TCF4, and ZEB1 implicated in its development.

Fuchs Endothelial Corneal Dystrophy (FECD) Diagnosis

Diagnosis of FECD involves clinical examination, in vivo imaging, and laboratory examination of removed corneas. Currently, slit lamp examination, specular microscopy, corneal thickness measurement, and confocal microscopy are used to identify FECD. There is a huge unmet medical need to improve the sensitivity of testing in the early stages. Although various tools are developed to improve disease diagnosis at an early stage such as deep learning algorithms and techniques like Scheimpflug tomography and anterior segment optical coherence tomography (AS-OCT), there is still a need to improve the availability and accessibility of these image analysis tools for early detection, monitoring of disease progression, and customized therapeutic interventions.

Further details related to diagnosis are provided in the report...

Fuchs Endothelial Corneal Dystrophy (FECD) Treatment

Medical management of early FECD is limited to decreasing corneal edema with topical sodium chloride 5% drops, hypertonic saline drops, and solutions (ophtasyloxane) or ointments to shorten the morning edema and facilitate corneal dehydration. Phototherapeutic keratectomy, amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps are also used to relieve painful symptoms, especially those associated with ruptured bullae in the later stages of the disease. Even cycloplegic, antibiotic ointment and patching are prescribed to treat ruptured corneal bullae. If a persistent or large epithelial defect is there, then bandage contact lenses are recommended.

However, these treatments do not have any curative effect because they do not act on the cause of the disease, which is the dysfunction of the endothelial layer. Frequency of usage has no effect; it only provides temporary relief and does not change the course of the disease; also, there is a stinging associated with these agents, which reduces acceptance.

Further details related to treatment are provided in the report...

Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology

As the market is derived using the patient-based model, the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of FECD, Gender-specific Cases of FECD, Age-specific Cases of FECD, and Grade-specific Cases of FECD in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

• DelveInsight's analyst estimate that approximately 18.9 million Diagnosed Prevalent Cases of FECD were found in 2022 in the 7MM.
• The United States exhibited the highest diagnosed prevalent population of FECD, as compared to other 7MM countries. As per DelveInsight's estimations, the Total Diagnosed Prevalent Cases of FECD in the US was around 6.5 million in 2022 and is projected to increase during the forecast period owing to the increasing awareness among the prevalent population.
• According to DelveInsight's estimates, the Total Diagnosed Prevalent Cases of FECD in EU4 and the UK were found to be 9.2 million in 2022. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of FECD cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.
• The estimates show the Total Diagnosed Prevalent Cases of FECD in Japan was found to be around 3 million in 2022, which is estimated to decrease by 2034 because of the decreasing country population.
• The Gender-specific Cases of FECD in the 7MM were ~12.3 million for females and ~6.6 million for males in 2022 and are expected to increase within the forecast period (2023-2034). The increased prevalence in females is likely due to a combination of factors, including gender differences in behavior and neural development, and others.
• According to the analysis performed by DelveInsight's experts, the Age-specific Cases of FECD were categorized into 40-49, 50-59, 60-69, 70-79, and =80 years. The higher number of cases (~1.9 million) was accounted for by the 50-59 year age group in 2022 in the US.
• The Grade-specific Cases of FECD were categorized into Grade 1-3 and Grade 4-6. According to DelveInsight estimates, patients with Grade 1-3 FECD were higher (~6.8 million) than patients with Grade 4-6 FECD (~2.4 million) in the EU4 and the UK.

Fuchs Endothelial Corneal Dystrophy (FECD) Drug Chapters

The drug chapter segment of the FECD report encloses a detailed analysis of FECD marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands FECD clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

Ripasudil (K-321): Kowa Pharmaceuticals

Ripasudil (K-321), being developed by Kowa Pharmaceuticals, is a rho-kinase inhibitor that lowers intraocular pressure (IOP) by increasing conventional aqueous outflow. Rho-associated protein kinase (ROCK) is a protein that regulates the shape and movement of cells in several tissues, including the eye. This drug is the only Phase III product for FECD, besides having an early mover advantage, is the much-awaited therapy that is a nonsurgical alternate to address the complications due to corneal transplantation.

TTHX 1114: Trefoil Therapeutics

Trefoil Therapeutics' nonsurgical therapy, TTHX 1114, an engineered FGF-1, is one of the best emerging therapies being developed for FECD. With a targeted intracameral injection route of administration, this cell proliferation stimulator has the ability to restore vision loss while reducing the risk of transplant failure. Its excellent Phase II results make it one of the most anticipated emerging therapies in the pipeline.

Note: Detailed emerging therapies assessment will be provided in the final report of Fuchs Endothelial Corneal Dystrophy (FECD).

Fuchs Endothelial Corneal Dystrophy (FECD) Market Outlook

FECD has a diverse treatment classification associated with the disease landscape. The management of FECD primarily revolves around the utilization of hyperosmotic sodium chloride, steroids, and others as needed.

Standard of care (Hyperosmotic sodium chloride, Steroids, etc.) is the major revenue generator in the current treatment landscape.

The market for FECD is expected to experience positive growth with the approval of potential drugs like Ripasudil/K-321, TTHX1114/NM141, and others.

• The total market size of FECD in the 7MM reached approximately USD 850 million in 2022. Projections indicate a substantial growth during the forecast period.
• Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 46%.
• In 2022, EU4 and the UK captured an estimated USD 330 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2022, followed by Italy, France, and the UK. Spain accounted for the least market in the same year.
• Japan alone represented approximately 16% of the total FECD market in 2022, projected to increase at a substantial CAGR during the study period.
• The total market size of the FECD treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Fuchs Endothelial Corneal Dystrophy (FECD) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, TTHX1114/ NM141 in the US is expected to be launched by 2025.

Further detailed analysis of emerging therapies drug uptake in the report...

Fuchs Endothelial Corneal Dystrophy (FECD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for FECD emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on FECD evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Jules Stein Eye Institute/UCLA, Los Angeles, Fight for Sight, New York, Department of Pharmacology and Biochemistry, UT Southwestern Medical Center, Texas, Philadelphia Eye Associates and Wills Eye Hospital, Philadelphia, Eye Center, Faculty of Medicine, University of Freiburg, Freiburg, Moorfields Eye Hospital, London, Kyoto Prefectural University of Medicine, Kyoto, and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or FECD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Fuchs Endothelial Corneal Dystrophy (FECD), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Fuchs Endothelial Corneal Dystrophy (FECD) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Fuchs Endothelial Corneal Dystrophy (FECD) market.

Fuchs Endothelial Corneal Dystrophy (FECD) Report Insights

• Patient Population
• Therapeutic Approaches
• Fuchs Endothelial Corneal Dystrophy (FECD) Pipeline Analysis
• Fuchs Endothelial Corneal Dystrophy (FECD) Market Size and Trends
• Existing and Future Market Opportunity

Fuchs Endothelial Corneal Dystrophy (FECD) Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Fuchs Endothelial Corneal Dystrophy (FECD) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the Fuchs Endothelial Corneal Dystrophy (FECD) total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of Fuchs Endothelial Corneal Dystrophy (FECD)?
• What are the patents of emerging therapies for Fuchs Endothelial Corneal Dystrophy (FECD)?
• Which drug is going to be the largest contributor by 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Fuchs Endothelial Corneal Dystrophy (FECD)? What will be the growth opportunities across the 7MM concerning the patient population of Fuchs Endothelial Corneal Dystrophy (FECD)?
• What is the historical and forecasted Fuchs Endothelial Corneal Dystrophy (FECD) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Fuchs Endothelial Corneal Dystrophy (FECD) and why?
• What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Fuchs Endothelial Corneal Dystrophy (FECD)? What are the current guidelines for treating Fuchs Endothelial Corneal Dystrophy (FECD) in the US and Europe?
• How many companies are developing therapies for treating Fuchs Endothelial Corneal Dystrophy (FECD)?
• How many emerging therapies are in the mid-stage and late stage of development for treating Fuchs Endothelial Corneal Dystrophy (FECD)?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Fuchs Endothelial Corneal Dystrophy (FECD)?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted markets of Fuchs Endothelial Corneal Dystrophy (FECD)?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Fuchs Endothelial Corneal Dystrophy (FECD) Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market?

The Fuchs Endothelial Corneal Dystrophy (FECD) market is quite robust. The major layers are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, and others which are currently developing drugs for the treatment of Fuchs Endothelial Corneal Dystrophy (FECD).

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Fuchs Endothelial Corneal Dystrophy (FECD) market?

The increase in diagnosed prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) and the launch of emerging therapies are attributed to be the key drivers for increasing Fuchs Endothelial Corneal Dystrophy (FECD) market.

5. What is the expected impact of emerging therapies or advancements in Fuchs Endothelial Corneal Dystrophy (FECD) treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Fuchs Endothelial Corneal Dystrophy (FECD) treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Fuchs Endothelial Corneal Dystrophy (FECD) market.

Table of Contents

1. Key Insights

2. Report Introduction

3. FECD Market Overview at a Glance

• 3.1. Market Share (percent) Distribution of FECD in 2020
• 3.2. Market Share (percent) Distribution of FECD in 2034

4. Methodology of FECD Epidemiology and Market

5. Executive Summary of FECD

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types of Corneal Dystrophies
• 7.3. Clinical Manifestations
• 7.4. Signs and Symptoms
• 7.5. Risk Factors
• 7.6. Genetics and Inheritance
• 7.7. Pathogenesis
• 7.8. Prognosis
• 7.9. Staging
• 7.10. Diagnosis
  • 7.10.1. Diagnostic criteria
  • 7.10.2. Differential diagnosis
• 7.11. Treatment and Management

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
  • 8.2.1. Total Diagnosed Prevalent Cases of FECD
  • 8.2.2. Gender-specific Cases of FECD
  • 8.2.3. Age-specific Cases of FECD
  • 8.2.4. Grade-specific Cases of FECD
• 8.3. Total Diagnosed Prevalent Cases of FECD in the 7MM
• 8.4. The US
  • 8.4.1. Total Diagnosed Prevalent Cases of FECD in the US
  • 8.4.2. Gender-specific Cases of FECD in the US
  • 8.4.3. Age-specific Cases of FECD in the US
  • 8.4.4. Grade-specific Cases of FECD in the US
• 8.5. The EU4 and the UK
  • 8.5.1. Total Diagnosed Prevalent Cases of FECD in the EU4 and the UK
  • 8.5.2. Gender-specific Cases of FECD in the EU4 and the UK
  • 8.5.3. Age-specific Cases of FECD in the EU4 and the UK
  • 8.5.4. Grade-specific Cases of FECD in the EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of FECD in Japan
  • 8.6.2. Gender-specific Cases of FECD in Japan
  • 8.6.3. Age-specific Cases of FECD in Japan
  • 8.6.4. Grade-specific Cases of FECD in Japan

9. Patient Journey

10. Emerging Drugs

• 10.1. Key Cross Competition
• 10.2. Ripasudil (K-321): Kowa Pharmaceuticals
  • 10.2.1. Drug description
  • 10.2.2. Other development activities
  • 10.2.3. Clinical development
  • 10.2.4. Clinical trials information
  • 10.2.5. Product profile
  • 10.2.6. Analysts' views
• 10.3. TTHX 1114: Trefoil Therapeutics
  • 10.3.1. Drug description
  • 10.3.2. Other development activities
  • 10.3.3. Clinical development
  • 10.3.4. Clinical trials information
  • 10.3.5. Safety and efficacy
  • 10.3.6. Product profile
  • 10.3.7. Analysts' Views

11. FECD: Market Analysis

• 11.1. Key Findings
• 11.2. Key Market Forecast Assumptions
• 11.3. Market Outlook
• 11.4. Conjoint Analysis
• 11.5. Market Size of FECD in 7MM
• 11.6. Market Size of FECD by Therapies in the 7MM
• 11.7. Market Size of FECD in the US
  • 11.7.1. Total Market Size of FECD
  • 11.7.2. Market Size of FECD by Therapies
• 11.8. Market Size of FECD in the EU4 and the UK
  • 11.8.1. Germany
    • 11.8.1.1. Total Market Size of FECD
    • 11.8.1.2. Market Size of FECD by Therapies
  • 11.8.2. France
    • 11.8.2.1. Total Market Size of FECD
    • 11.8.2.2. Market Size of FECD by Therapies
  • 11.8.3. Italy
    • 11.8.3.1. Total Market Size of FECD
    • 11.8.3.2. Market Size of FECD by Therapies
  • 11.8.4. Spain
    • 11.8.4.1. Total Market Size of FECD
    • 11.8.4.2. Market Size of FECD by Therapies
  • 11.8.5. The UK
    • 11.8.5.1. Total Market Size of FECD
    • 11.8.5.2. Market Size of FECD by Therapies
• 11.9. Market Size of FECD in Japan
  • 11.9.1. Total Market Size of FECD
  • 11.9.2. Market Size of FECD by Therapies

12. KOL Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access

• 15.1. The United States
  • 15.1.1. CMS
• 15.2. The EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. The United Kingdom
• 15.3. Japan
  • 15.3.1. MHLW

16. Appendix

• 16.1. Bibliography
• 16.2. Acronyms and Abbreviations
• 16.3. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight